We are live on ! Find out more
ORPH

Orphazyme A/S
ORPH

Delisted

ORPH was delisted on the 30th of March, 2022.

Back to rankings

1 hedge funds and large institutions have $0 invested in Orphazyme A/S in 2022 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 0 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% less funds holding

Funds holding: 4 → 1 (-3)

100% less capital invested

Capital invested by funds: $8K → $0 (-$8K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 3

Holders
1
Holders Change
-3
Holders Change %
-75%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Optiver Holding
Optiver Holding
Netherlands
-$6K
2
Simplex Trading
Simplex Trading
Illinois
-$2K

ORPH Hedge Fund Activity: Q2 2022 in Review

1 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Orphazyme A/S (ORPH) for Q2 2022, worth a combined $0 — down 100% from $8K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of ORPH and 0 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Optiver Holding, exiting entirely with an estimated $6K sold.

  • 1 institutional investor held Orphazyme A/S (ORPH) as of Q2 2022, down from 4 in Q1 2022.
  • Funds reported $0 of Orphazyme A/S stock for Q2 2022, down 100% quarter-over-quarter.
  • 0 funds opened new Orphazyme A/S positions in Q2 2022 and 3 closed out, a net change of -3 holders.
  • The largest Orphazyme A/S seller in Q2 2022 was Optiver Holding, an estimated $6K sold.

Based on aggregated 13F filings for Q2 2022.